# Relapse Prevention Study in Patients With Schizophrenia

> **NCT01291511** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 635 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Iloperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01291511
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-03
- **Final completion:** 2015-03
- **Target enrollment:** 635 (ACTUAL)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01291511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01291511, "Relapse Prevention Study in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01291511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*